274 related articles for article (PubMed ID: 22409819)
1. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
Frick M; Dörken B; Lenz G
Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
[TBL] [Abstract][Full Text] [Related]
2. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens.
Carey CD; Gusenleitner D; Chapuy B; Kovach AE; Kluk MJ; Sun HH; Crossland RE; Bacon CM; Rand V; Dal Cin P; Le LP; Neuberg D; Sohani AR; Shipp MA; Monti S; Rodig SJ
J Mol Diagn; 2015 Jan; 17(1):19-30. PubMed ID: 25468432
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
5. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
Jaradat JM; Potluri A; Bilodeau EA
Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
Maruyama D
Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
[No Abstract] [Full Text] [Related]
7. [Prognostic impact of bone marrow involvement (BMI) and therapies in diffuse large B cell lymphoma].
Yi SH; Xu Y; Zou DH; An G; Zhao YZ; Qi JY; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):307-12. PubMed ID: 19799125
[TBL] [Abstract][Full Text] [Related]
8. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD
Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
10. Diffuse large B cell lymphoma: how can we cure more patients in 2012?
Moskowitz C
Best Pract Res Clin Haematol; 2012 Mar; 25(1):41-7. PubMed ID: 22409822
[TBL] [Abstract][Full Text] [Related]
11. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
Fabbri A; Gozzetti A; Rigacci L
Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
[No Abstract] [Full Text] [Related]
12. Double-hit diffuse large B-cell lymphoma.
Friedberg JW
J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
[No Abstract] [Full Text] [Related]
13. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru.
Beltran BE; Castillo JJ; Morales D; de Mendoza FH; Quinones P; Miranda RN; Gallo A; Lopez-Ilasaca M; Butera JN; Sotomayor EM
Am J Hematol; 2011 Aug; 86(8):663-7. PubMed ID: 21761432
[TBL] [Abstract][Full Text] [Related]
14. Front-line management of diffuse large B cell lymphoma.
Cabanillas F
Curr Opin Oncol; 2010 Nov; 22(6):642-5. PubMed ID: 20811278
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
[No Abstract] [Full Text] [Related]
16. Molecular outcome prediction in diffuse large-B-cell lymphoma.
Alizadeh AA; Gentles AJ; Lossos IS; Levy R
N Engl J Med; 2009 Jun; 360(26):2794-5. PubMed ID: 19553658
[No Abstract] [Full Text] [Related]
17. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Testoni M; Kwee I; Greiner TC; Montes-Moreno S; Vose J; Chan WC; Chiappella A; Baldini L; Ferreri AJ; Gaidano G; Mian M; Zucca E; Bertoni F
Br J Haematol; 2011 Oct; 155(2):274-7. PubMed ID: 21488860
[No Abstract] [Full Text] [Related]
18. Improving outcomes for patients with diffuse large B-cell lymphoma.
Flowers CR; Sinha R; Vose JM
CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
[TBL] [Abstract][Full Text] [Related]
19. Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
Chigrinova E; Mian M; Shen Y; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Zucca E; Kwee I; Bertoni F
Br J Haematol; 2011 May; 153(4):499-503. PubMed ID: 21418177
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
Reiter A; Klapper W
Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]